Literature DB >> 22736262

[Spectral domain OCT in central serous chorioretinopathy: description of retinal changes].

V Valet1, C P Lohmann, M Maier.   

Abstract

BACKGROUND: The aim was to describe the morphological alterations of the retina seen in spectral domain optical coherence tomography (SD-OCT) of eyes with central serous chorioretinopathy (CSC). PATIENTS AND METHODS: Data of patients in the database with CSC examined with SD-OCT scans (n = 50) and fluorescein angiography (FA) were analyzed for representative cases exhibiting significant changes of the retinal structure allowing a direct comparison of SD-OCT with FA images and a description of the findings.
RESULTS: Apart from the 3 well-known CCS types [type I shows only subretinal fluid (SRF), type II only serous pigment epithelial detachment (PED) and the intermediate type showing both SRF and PED] hybrid forms were also observed in multifocal CSC, for example type I and type II next to each other. Of the patients 1 showed transformation from type II to type I over a period of 3 months. Small bulges of the retinal pigment epithelium (RPE) seen in OCT images could be angiographically related to leakage spots. Degenerative changes with subretinal granular sediments, patchy defects in the photoreceptor layer, granular alterations of the RPE and atrophy of the RPE and neuroretina were particularly observed in chronic CSC.
CONCLUSION: Spectral domain OCT is a valuable imaging technology enabling detailed visualization of retinal changes in patients with CSC. It gives access to a better understanding of the disease mechanisms and may provide a new approach to the classification and understanding of CSC.

Entities:  

Mesh:

Year:  2012        PMID: 22736262     DOI: 10.1007/s00347-012-2588-x

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  30 in total

1.  Optical coherence tomography characterisation of idiopathic central serous chorioretinopathy.

Authors:  J A Montero; J M Ruiz-Moreno
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

2.  [Three-dimensional imaging in central serous chorioretinopathy].

Authors:  G Stock; C Ahlers; R Sayegh; M Ritter; S Kolar; I Golbaz; U Schmidt-Erfurth
Journal:  Ophthalmologe       Date:  2008-12       Impact factor: 1.059

3.  Single-session combined photodynamic therapy with verteporfin and intravitreal anti-vascular endothelial growth factor therapy for chronic central serous chorioretinopathy: a pilot study at 12-month follow-up.

Authors:  J Fernando Arevalo; Juan V Espinoza
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2011-03-30       Impact factor: 3.117

4.  Retinal atrophy in idiopathic central serous chorioretinopathy.

Authors:  Maria S M Wang; Birgit Sander; Michael Larsen
Journal:  Am J Ophthalmol       Date:  2002-06       Impact factor: 5.258

5.  Three-dimensional optical coherence tomographic findings in central serous chorioretinopathy.

Authors:  Keiichi Mitarai; Fumi Gomi; Yasuo Tano
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-04-05       Impact factor: 3.117

6.  Fundus autofluorescence and central serous chorioretinopathy.

Authors:  Richard F Spaide; James M Klancnik
Journal:  Ophthalmology       Date:  2005-05       Impact factor: 12.079

7.  Evaluation of central serous retinopathy with en face optical coherence tomography.

Authors:  M E J van Velthoven; F D Verbraak; P M Garcia; R O Schlingemann; R B Rosen; M D de Smet
Journal:  Br J Ophthalmol       Date:  2005-11       Impact factor: 4.638

8.  Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level.

Authors:  W-M Chan; D S C Lam; T Y Y Lai; B S M Tam; D T L Liu; C K M Chan
Journal:  Br J Ophthalmol       Date:  2003-12       Impact factor: 4.638

Review 9.  Type-A behavior and central serous chorioretinopathy.

Authors:  L A Yannuzzi
Journal:  Retina       Date:  1987       Impact factor: 4.256

10.  Morphologic changes in acute central serous chorioretinopathy evaluated by fourier-domain optical coherence tomography.

Authors:  Hisataka Fujimoto; Fumi Gomi; Taku Wakabayashi; Miki Sawa; Motokazu Tsujikawa; Yasuo Tano
Journal:  Ophthalmology       Date:  2008-04-18       Impact factor: 12.079

View more
  2 in total

1.  [Mineralocorticoid receptor antagonists as treatment option for acute and chronic central serous chorioretinopathy].

Authors:  M Maier; S Stumpfe; N Feucht; P Strobl; V Rath; C P Lohmann
Journal:  Ophthalmologe       Date:  2014-02       Impact factor: 1.059

Review 2.  [Central serous chorioretinopathy].

Authors:  Laurenz Pauleikhoff; Hansjürgen Agostini; Clemens Lange
Journal:  Ophthalmologe       Date:  2021-04-16       Impact factor: 1.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.